

FIVE PRIME THERAPEUTICS INC
 Form 4
 January 29, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Sarena Francis Willard

2. Issuer Name and Ticker or Trading Symbol
 FIVE PRIME THERAPEUTICS INC [FPRX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 01/27/2016

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 EVP, Gen Counsel & Secretary

C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ____ Form filed by More than One Reporting Person

SOUTH SAN FRANCISCO, CA 94080

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	01/27/2016		M	9,479 A \$ 11.14	93,049	D	
Common Stock	01/27/2016		S ⁽¹⁾	6,895 D \$ 35.55	86,154	D	
Common Stock	01/27/2016		S ⁽¹⁾	2,584 D \$ 36.13	83,570	D	
	01/27/2016		M	3,791 A \$	87,361	D	

Edgar Filing: FIVE PRIME THERAPEUTICS INC - Form 4

Common Stock						\$ 10.77	
Common Stock	01/27/2016	S ⁽¹⁾	3,791	D		\$ 35.31 <u>(4)</u>	83,570 D
Common Stock	01/27/2016	M	7,449	A		\$ 7.26	91,019 D
Common Stock	01/27/2016	S ⁽¹⁾	7,449	D		\$ 35.11 <u>(5)</u>	83,570 D
Common Stock	01/27/2016	M	7,768	A		\$ 5.54	91,338 D
Common Stock	01/27/2016	S ⁽¹⁾	7,768	D		\$ 34.73 <u>(6)</u>	83,570 D
Common Stock	01/27/2016	M	1,513	A		\$ 8.49	85,083 D
Common Stock	01/27/2016	S ⁽¹⁾	1,513	D		\$ 35	83,570 D
Common Stock							83,834 <u>(7)</u> D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Employee Stock Option	\$ 11.14	01/27/2016		M	9,479	<u>(8)</u> 08/21/2024	Common Stock	9,479

(right to buy)

Employee

Stock

Option

\$ 10.77

01/27/2016

M

3,791

(9)

11/04/2023

Common
Stock

3,791

(right to buy)

Employee

Stock

Option

\$ 7.26

01/27/2016

M

7,449

(10)

07/18/2023

Common
Stock

7,449

(right to buy)

Employee

Stock

Option

\$ 5.54

01/27/2016

M

7,768

(11)

07/15/2022

Common
Stock

7,768

(right to buy)

Employee

Stock

Option

\$ 8.49

01/27/2016

M

1,513

(12)

07/13/2021

Common
Stock

1,513

(right to buy)

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Sarena Francis Willard
C/O FIVE PRIME THERAPEUTICS, INC.
TWO CORPORATE DRIVE
SOUTH SAN FRANCISCO, CA 94080

EVP, Gen Counsel & Secretary

Signatures

/s/ Marc Belsky,
Attorney-in-Fact

01/29/2016

 Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 27, 2015.

(2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$35.02 to \$36.01, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.

Edgar Filing: FIVE PRIME THERAPEUTICS INC - Form 4

- (3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$36.02 to \$36.71, inclusive.
- (4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$34.85 to \$35.76, inclusive.
- (5) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$34.83 to \$35.49, inclusive.
- (6) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$34.16 to \$35.01, inclusive.
- (7) Includes 264 shares granted to the reporting person by the Company pursuant to a company match under the Company's 401(k) plan.
- (8) This option began vesting on September 22, 2014, at a rate of 1/48th per month.
The option was vested with respect to one sixteenth of the shares underlying the option on the date of the grant, November 5, 2013. The remainder of the shares underlying the option vest at a rate of 1/48th of the total number of shares underlying the option per month beginning November 19, 2013.
- (9) This option began vesting on July 19, 2013, at a rate of 1/48th per month.
- (10) This option began vesting on July 12, 2012, at a rate of 1/48th per month.
- (11) This option began vesting on July 14, 2011, at a rate of 1/48th per month.
- (12) This option began vesting on July 14, 2011, at a rate of 1/48th per month.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.